Name | Type | Posted | Actions |
|---|---|---|---|
RFP 75A50121R00013 Pages 1-2 9-10-2021.pdf | Sep 10, 2021 | ||
Amendment 4 - Summary.pdf | Sep 10, 2021 | ||
RFP SOW-New Stockpile Updated with Responses 9-2-2021.pdf | Sep 3, 2021 | ||
New Email Account 8-29-2021.pdf | Aug 29, 2021 | ||
Amendment 3 - Past Performance Update v1.pdf | Aug 26, 2021 | ||
Amendment 3 - Past Performance Update.pdf | Aug 25, 2021 | ||
Response - Proposal Ext.pdf | Aug 18, 2021 | ||
QA for Follow-On Stockpile - Additional Questions - 8-16-21 FINAL .pdf | Aug 17, 2021 | ||
QA for Follow Stockpile - IDIQ 8-6-21 FINAL.pdf | Aug 7, 2021 | ||
Amendment 2 - Summary.docx | DOCX | Jul 26, 2021 | |
RFP SOW-New Stockpile 6-29-2021 - Amendment 1.pdf | Jul 23, 2021 | ||
Amendment 1 - Summary.pdf | Jul 23, 2021 | ||
RFP SOW-New Stockpile 6-29-2021 - Program Updated - CLEAN.pdf | Jun 29, 2021 |
Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response
Contact and place of performance
Wendell Conyers
DC
USA
Reference Amendment 1 PERIOD OF PERFORMANCE a. The base period of performance of this contract is anticipated for thirty-six (36) monthsfrom date of award. The period of performance may be extended up to 24 months withthe exercise of option(s), structured as CLINs. b. If the Government exercises its option(s), the period of performance will be increased as listed below: Option I Twelve (12) Months (Year 4) Option II...
View moreThe Office of the Assistant Secretary for Preparedness and Response (ASPR), specifically the BARDA Division of Contracts Management and Acquisition, is soliciting medical countermeasures for pandemic influenza and emerging diseases preparedness and response under solicitation number 75A50121R00013. This requirement is classified under NAICS 325414 Biological Product (except Diagnostic) Manufacturing and PSC 6505 DRUGS AND BIOLOGICALS. The scope includes providing yield-optimized master and working seed lots for inactivated, live attenuated, or recombinant influenza vaccines, along with research, investigational, and commercial scale bulk lots. Contractors must also provide adjuvants that have completed Phase 2 development and demonstrated clinical evidence of antigen-sparing benefits.
The performance involves formulation and filling services for antigens and adjuvants in single-dose vials, multi-dose vials, syringes, and sprayers. Additional requirements cover storage and stability testing for materials from new and prior contracts, candidate vaccine virus provision, potency reagent manufacture, analytical laboratory testing, and both clinical and non-clinical studies. The contractor is responsible for standard data reporting and executing activities for emerging pathogens as specified in government requests for task order responses. The notice includes 13 attachments, including several amendments, a statement of work, and past performance updates.
Place of performance is Washington, DC, and responses are due by September 13, 2021. The contract features an anticipated 36-month base period with two 12-month options, potentially extending performance to 60 months. The minimum guarantee for the duration of the contract is $50,000. While most line items require firm-fixed pricing, costs for shipping, laboratory testing, and clinical studies will be determined through individual task order responses issued to awardees.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.